ACADIA Pharmaceuticals’ (ACAD) “Outperform” Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada reaffirmed their outperform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $26.00 price target on the biopharmaceutical company’s stock. Several other analysts have also issued reports on ACAD. BMO Capital Markets increased their price […]
Royal Bank of Canada reaffirmed their outperform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $26.00 price target on the biopharmaceutical company’s stock. Several other analysts have also issued reports on ACAD. BMO Capital Markets increased their price […]
